Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 May 2012: Basic Research  

Intracerebellar application of P19-derived neuroprogenitor and naive stem cells to Lurcher mutant and wild type B6CBA mice

Zbyněk Houdek B , Jan Cendelín ABCDEF , Vlastimil Kulda B , Václav Babuška B , Miroslava Čedíková B , Milena Králíčková ADE , Jiří Pacherník D , George B. Stefano EF , František Vožeh EG

DOI: 10.12659/MSM.882726

Med Sci Monit 2012; 18(5): BR174-180

0 Comments

Background

Neurotransplantation has great potential for the future treatment of various neurological/neurodegenerative diseases. Preclinical studies have utilized several approaches and different stem cell lines. Nevertheless, determination of appropriate stem cell lines as the ideal source for brain-specific restorative neural grafts remains an unsolved problem. Second, it is necessary to elucidate cellular mechanisms by which stem cell transplantation leads to functional recovery and structural reorganization.

The biological risks of carcinoma stem cells are obvious due to their potential to form donor-derived malignant tumors in the host. On the other hand, it has been previously shown that, when differentiated, carcinoma-derived stem cells lose tumorigenic capacity [1]. Furthermore, it has been previously demonstrated that transplantation of neurons derived from a human teratocarcinoma-derived cell line are potentially beneficial in several animal models of neurological disorders [1], including ischemia-induced injury [2], spinal cord injury [3], stroke [4–6], Parkinson’s disease [7], Huntington’s disease [8] and amyotrophic lateral sclerosis [1].

In light of the above, there exists a wide spectrum of human cerebellar ataxias with different pathogenetic etiologies [9,10], as well as established animal models of cerebellar disorders [11–13]. Despite several therapeutic strategies for spinocerebellar ataxias, none of them is effective enough to stop the degenerative process with substantial recovery of diminished cerebellar function [14,15]. Promising approaches include gene transfer into the cerebellum to prevent the degeneration of Purkinje cells [16] and neurotransplantation to provide restorative cells and/or trophic effect of immature grafts (for review, see [17]).

The Lurcher mutant mouse represents one of the most frequently used natural models of genetically-determined olivocerebellar degeneration [18]. They are heterozygotes (+/Lc), carrying a mutation in the glutamate receptor delta2-subunit gene [19], which is predominantly expressed by cerebellar Purkinje cells [20]. Lurcher mice suffer from a virtually complete postnatal loss of Purkinje cells and a decrease in the number of cerebellar granule, basket and stellate cells and inferior olive neurons [21,22]. The reduction in the Purkinje cell number can be detected from postnatal day 8 (P8) and the degeneration is finalized at the P90 [21]. The death of Purkinje cells is a primary effect of the mutation that changes the altered receptor into a leaky membrane channel, leading to chronic depolarization of the cells [19]. The degeneration of the other cerebellar cells and inferior olive neurons is a secondary consequence of the disappearance of target of their axons – the Purkinje cells [23,24] – and affects 90% of the granule cells and 70% of the inferior olive neurons [21].

Homozygous mutants (Lc/Lc) are not viable due to the massive loss of brainstem neurons during prenatal development and they die at birth [25,26]. Homozygous wild type littermates of Lurcher mice (+/+) are completely healthy and serve as controls. In contrast, heterozygous Lurcher mice suffer from cerebellar ataxia [27–29], a deterioration of spatial learning or orientation [30–33], and abnormalities in conditioned eyelid response [32,34]. For review, see [35–37]. We have recently shown that naive carcinoma stem cells and neuroprogenitors derived from these cells are able to survive in a normal mouse cerebellum, although there are some differences in growth character of these 2 types of grafts [38]. Accordingly, the aim of the present study was to assess survival of naive and neurally differentiated P19 carcinoma stem cells following transplantation into the cerebellum of Lurcher mice and wild type littermates.

Material and Methods

STEM CELL CULTURE AND NEURODIFFERENTIATION:

Embryonic carcinoma (EC) stem cells of the P19 line isolated from a teratocarcinoma induced in the C3H/He strain of mice [39] were purchased from the European Collection of Cell Culture, Wiltshire, UK. They were genetically modified to express the green fluorescent protein (GFP) so that they could subsequently be detected after transplantation in histological sections using direct fluorescent microscopy [38].

Undifferentiated EC cells were cultured on gelatin-coated tissue culture dishes in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum, 0.05 mM beta-mercaptoethanol, 100 i.u. /ml penicillin, and 0.1 mg/ml streptomycin (all GIBCO BRL, Chemos CZ, Prague, Czech Republic) [40].

For neurodifferentiation, the EC cells were cultured under serum-free conditions in DMEM/F12 (1:1) media supplemented with a mixture of insulin, transferrin, selenium (ITS) and antibiotics. For the first 2 days, the cells were treated with retinoic acid (RA, c=5×10−7 M) to induce neurogenesis and then they were cultured for 1 day without RA [40]. At that point, they were used as neuroprogenitors for transplantation.

We have previously described the characterization of naive P19 cells and neuroprogenitors in the stage in which they were grafted by immunocytochemical, Western blot and quantitative reverse transcriptase real-time PCR analyses [38,41].

GRAFT PREPARATIONS:

For transplantation of naive P19 cells or neuroprogenitors, the cells were isolated by trypsin, which was neutralized by adding DMEM with serum and then centrifuged and resuspended in DMEM to give a final cell concentration of 50 000 viable cells/μl. The cells were then grafted within 1 hour.

TRANSPLANTATIONS:

Transplantations were performed under general anaesthesia (Ketamine 100 mg/kg bw and Xylazine 16 mg/kg bw). A hole (2 mm in diameter) was drilled in the occipital bone (Bregma – 6.5–7.0 mm, midline), and 1 μl of cell suspension (a total amount of 50 000 cells) was injected with a Hamilton syringe at a constant speed of 0.5 μl/min. The tip of the needle was inserted 1.6 mm under the surface of the cerebellum in wild type mice and 1.6 or 1.2 mm in Lurcher mice. In the Lurcher mouse, the cerebellum is flattened, necessitating a lower depth of implantation. During the injection of the cell suspension, the tip was elevated 0.1 mm. Upon completion of the administration, the needle remained in situ for 5 minutes to prevent the return of the cells out of the host head. Finally, the wound was sutured by 1 layer with Chirlac rapid (Chirmax GmbH) and disinfected.

HISTOLOGICAL EXAMINATION:

Mice were sacrificed 21 days after the transplantation by a lethal dosage of Thiopental and were transcardially perfused with phosphate-buffered saline solution (pH 7.4) and 4% phosphate-buffered paraformaldehyde. Fixed brainstem and cerebellar blocks were sectioned using a cryostat (40 μm frontal sections). The grafts were detected according to their GFP fluorescence in the native sections under a fluorescent microscope. Sections were counter-stained with hematoxylin-eosin or according to the Nissl technique to visualize the histological structure of the graft and surrounding host tissue [38].

Detection and quantification of Purkinje cells and astrocytes was achieved via immunohistochemical staining utilizing a rabbit anti-calbindin-D-28K antiserum (Sigma-Aldrich, St. Louis, USA) and a mouse monoclonal glial fibrillary acidic protein (GFAP) antiserum (clone G-A-5, Sigma-Aldrich, St. Louis, USA), respectively.

In the immunohistochemical analyses, sections were incubated in PBS with 10% normal serum, 0.5% Tween and 0.1% FBS (foetal bovine serum) for 1 hour at room temperature. After washing in PBS, the sections were incubated overnight at 4°C with the primary antibody (dilution of GFAP 1:800 and anti-calbindin 1:1000). After a PBS wash, GFAP labelling was completed and the sections were mounted in ProLong Gold antifade reagent with DAPI (Invitrogen, Eugene, USA). Sections incubated with anti-calbindin antiserum were washed in PBS and subsequently incubated with the secondary antibody, Alexa Fluor 568 goat anti – rabbit IgG (final dilution 1:400, Invitrogen, Eugene, USA), for 2 hours at room temperature. After a PBS wash, sections were mounted in ProLong Gold antifade reagent with DAPI and viewed under an epifluorescent microscope (Olympus BX 41, Olympus Czech Group, Prague, Czech Republic).

STATISTICAL ANALYSIS:

The number and percentage of mice in which the graft survived (quantified by counting GFP-positive cells) and the frequency of the occurrence of various features of the grafts (localization of the graft, the destruction of the tissue, and the characteristic growth of the graft) were assessed. The differences between the groups of mice were evaluated using Fisher’s test. In all cases, the differences were considered significant at the p<0.05 level.

ANIMALS:

All animal experiments described in the present study were performed in full compliance with the EU guidelines for scientific experimentation on animals and with the permission of the Ethics Commission of the Faculty of Medicine at Charles University, Pilsen.

Adult normal wild type and Lurcher mutant mice of the B6CBA strain were used; 43 wild type mice were taken from the previous study [38]. The final number of wild type mice used in the present study was 51. The number of Lurcher mutant mice employed in the study was 87. The mean age of the animals at the time of transplantation was 261.5 days (SD=64.3 days, minimum =156 days, maximum =385 days). The mice were reared under standard conventional conditions with 12:12 hours light: dark cycle (6 am – 6 pm) and temperature 22–24°C. Water and food were available ad libitum. The mice were housed in plastic cages with metal mesh cover (11×25 cm, 14 cm high for 1–2 mice or 18×25 cm, 14 cm high for 2–4 mice). Twenty-five wild type mice (12 males and 13 females) were treated with naive P19 cells and 26 wild type animals (13 males and 13 females) received neuroprogenitor cells. In 25 Lurcher mice (12 males and 13 females) naive P19 cells were injected at the depth of 1.6 mm under the surface and in 18 Lurcher mice (9 males and 9 females) received neuroprogenitor cells injected at the depth of 1.2 mm. Twenty-five Lurcher mice (13 males and 12 females) received neuroprogenitor cells injected at the depth of 1.6 mm and 19 Lurcher mice (9 males and 10 females) received neuroprogenitor cells injected into the depth of 1.2 mm.

Results

GRAFT SURVIVAL:

The number and percentage of experimental animals with viable grafts are listed in Table 1. Notably, the number of viable neuroprogenitor cellular grafts at an injection depth of 1.6 mm was significantly higher in wild type as compared to Lurcher mutant mice (p=0.0078).

GRAFT LOCALIZATION:

Both P19 cell and neuroprogenitor grafts formed a separate mass containing GFP-positive cells dispersed in non-fluorescent tissue, as previously described for wild type mice [38].

In 11 and 7 wild type mice injected with neuroprogenitor and naive P19 cells, respectively, the graft was typically localized to the vicinity of the injection site in the middle of the cerebellum (Figure 1A). In 2 wild type mice injected with neuroprogenitor cells, viable grafts were localized to the mesencephalon. In a single animal, a viable graft was localized to an area between the cerebellum and the mesencephalon and was strictly delimited against both of these structures.

In Lurcher mice, viable grafts were localized to the mesencephalon and were never observed to be inside the cerebellum (Figure 1B). In 2 Lurcher mice injected with neuroprogenitor cells at a depth of 1.6 mm, viable grafts were observed to be in contact with the border between the mesencephalon and the cerebellum, with the mass of the graft strictly delimited against the cerebellum (Figure 1C). In a single Lurcher mouse injected with naive P19 cells at a depth of 1.6 mm, a large viable graft was observed in the mesencephalon and a small piece of fluorescent graft tissue was found at an angle between the pons and the cerebellum with no signs of direct contact with the cerebellum. Finally, in a single Lurcher mouse injected with neuroprogenitor cells at a depth of 1.2 mm, GFP-positive cells were observed in the mesencephalon and also on the surface of the medulla oblongata.

Localization parameters of viable cerebellar and mesencephalic neurografts are depicted in Table 2. Statistically significant differences were observed in the cerebellar localization of viable grafts in Lurcher mutants in comparison to wild type littermates (for neuroprogenitor graft, depth 1.6 mm p=0.0063, for naive P19 cells, depth 1.6 mm p=0.0101).

GRAFT STRUCTURE:

Immunohistochemical analyses demonstrated that viable grafts contained numerous GFAP-positive cells (Figure 2B, D), at least some of which were GFP-positive (Figure 2A, C). Calbindin-positive cells co-expressing GFP fluorescence were not observed in viable grafts.

In some of the animals, tissue destruction was observable inside viable grafts, whereas other viable grafts exhibited expansive morphological characteristics [38]. The tabulated number of viable grafts exhibiting these morphological characteristics is depicted in Table 3.

In wild type mice, expansive character was more frequent in mice that received naive P19 cells than in those treated with the neuroprogenitors (p=0.0017). Differences in intragraft tissue destruction in viable grafts originating from naive P19 cell and the neuroprogenitor cell injections to wild type mice did not reach statistical significance. Due to the low number of surviving grafts in Lurcher mice, it was not possible to perform reliable statistical analysis of various morphological features of the grafts.

Discussion

The present study confirms and elaborates previous preliminary findings that have described cerebellar transplantation of naive P19 carcinoma stem cells and P19-derived neuroprogenitors in wild type mice [38] by including similar analyses in Lurcher mutant mice. Our major observations indicate that in Lurcher mice graft survival is quite poor and survival rate of the neuroprogenitor grafts is significantly lower in comparison to wild type mice when injected at the same tissue depth. The low number of surviving grafts did not allow for a more detailed comparison of morphological characteristics of the 2 types of grafts in Lurcher mice. We can conclude, however, that naive P19 cell grafts typically exhibited expansive morphological characteristics without intragraft tissue destruction in both wild type and Lurcher mice. In these parameters, Lurcher mice did not differ significantly from wild type individuals. The characteristic features of the 2 types of grafts have already been discussed elsewhere [38].

The main finding of the present study was the observed regional difference in graft localization between wild type and Lurcher mice. It is notable that in Lurcher mice, viable grafts were localized to the mesencephalon and were never observed to be inside the cerebellum. This may be attributable to technical limitations due to the flattened cerebellum of the Lurcher mutant mouse. In the Lurcher mouse cerebellum, there is much less space for viable graft development than in wild type animals and the cerebellum could be easily missed by the tip of the injection needle. Moreover, the depth of cell injection suitable for wild type mice could be too deep for the Lurcher cerebellum. These anatomical factors could also play a role in the difference in neuroprogenitor graft survival between Lurcher mutant and wild type mice. On the other hand, an apparent doubling of survival rate of the neuroprogenitor grafts when injected at the lower depth of 1.2 mm vs. 1.6 mm, together with a lower graft survival in Lurcher as compared to wild type mice, suggests that the niche of the Lurcher cerebellum is less suitable for the grafted cells than the adjacent mesencephalon. These intrinsic difficulties suggest that neurodegenerative changes of the cerebellar tissue could have a negative impact on the fate of stem cells grafted into the cerebellum of adult Lurcher mice.

The area of the graft contained numerous astrocytes, at least some of which were donor-derived. Additionally, we have no evidence that the grafted cell (naive embryonic carcinoma cells or neuroprogenitors) differentiated into the Purkinje cells, the main cell type that is missing in Lurcher mutant mice.

Survival of embryonic carcinoma stem cells in Lurcher mice is much lower than the survival of embryonic cerebellar tissue. Tomey and Heckroth [42], who transplanted a suspension of embryonic cerebellar cells, found surviving graft in 50% of both young and adult Lurcher mice 1–2 months after transplantation. The survival of solid embryonic cerebellar graft 3–9 weeks after the surgery was 80–90% in Lurcher mice and it did not differ from wild type mice [43]. However, cells grafted in the form of suspension are in direct and closer contact with the host tissue than cells inside the solid grafts. Therefore, the influence of the host tissue on grafted cells development is stronger in cell suspension than in solid grafts. Solid grafts are not as suitable as cell suspension for an investigation of the impact of the host environment on the fate of the grafted cells [44]. In addition, the solid embryonic cerebellar graft mediated controversial behavioural effects in Lurcher mice [45].

Conclusions

The appearance and low survival rate of the grafts do not show any promise for a sufficient therapeutic effect on cerebellar function that has deteriorated due to degenerative disease in Lurcher mice. This is in contrast to the findings of benefit of transplantation of neurons derived from the human teratocarcinoma cell-line in animal models of several other neurological diseases [1,6].

References

1. Garbuzova-Davis S, Willing AE, Milliken M, Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis: Exp Neurol, 2002; 174; 169-80, pmid: 11922659

2. Borlongan CV, Tajima Y, Trojanowski JQ, Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats: Exp Neurol, 1998; 149; 310-21, pmid: 9500961

3. Saporta S, Makoui AS, Willing AE, Functional recovery after complete contusion injury to the spinal cord and transplantation of human neuroteratocarcinoma neurons in rats: J Neurosurg, 2002; 97(1 Suppl); 63-68, pmid: 12120653

4. Meltzer CC, Kondziolka D, Villemagne VL, Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke: Neurosurgery, 2001; 49; 586-91, pmid: 11523668

5. Kondziolka D, Steinberg GK, Wechsler L, Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial: J Neurosurg, 2005; 103; 38-45, pmid: 16121971

6. Hara K, Matsukawa N, Yasuhara T: J Neurosci Res, 2007; 85; 1240-51, pmid: 17335085

7. Baker KA, Hong M, Sadi D, Mendez I, Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson’s disease: Exp Neurol, 2000; 162; 350-60, pmid: 10739641

8. Hurlbert MS, Gianani RI, Hutt C, Neural transplantation of hNT neurons for Huntington’s disease: Cell Transplant, 1999; 8; 143-51, pmid: 10338282

9. Manto MU, The wide spectrum of spinocerebellar ataxias (SCAs): Cerebellum, 2005; 4; 2-6, pmid: 15895552

10. Manto M, Marmolino D, Cerebellar disorders – at the crossroad of molecular pathways and diagnosis: Cerebellum, 2009a; 8; 417-22, pmid: 19859773

11. Lalonde R, Strazielle C, Spontaneous and induced mouse mutations with cerebellar dysfunctions: Behavior and neurochemistry: Brain Res, 2007; 1140; 51-74, pmid: 16499884

12. Manto M, Marmolino D, Animal models of human cerebellar ataxias: a cornerstone for the therapies of the twenty-first century: Cerebellum, 2009b; 8; 137-54, pmid: 19669387

13. Sajan SA, Waimey KE, Millen KJ, Novel approaches to studying the genetic basis of cerebellar development: Cerebellum, 2010; 9; 272-83, pmid: 20387026

14. Underwood BR, Rubinsztein DC, Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies: Cerebellum, 2008; 7; 215-21, pmid: 18418676

15. Marmolino D, Manto M, Past, present and future therapeutics for cerebellar ataxias: Curr Neuropharmacol, 2010; 8; 41-61, pmid: 20808545

16. Louboutin J-P, Reyes BAS, Van Bockstaele EJ, Strayer DS, Gene transfer to the cerebellum: Cerebellum, 2010; 9; 587-97, pmid: 20700772

17. Rossi F, Cattaneo E, Neural stem cell therapy for neurological diseases: dreams and reality: Nat Rev Neurosci, 2002; 3; 401-9, pmid: 11988779

18. Phillips RJS, ‘Lurcher’. A new gene in linkage group XI of the house mouse: J Genet, 1960; 57; 35-42

19. Zuo J, De Jager PL, Takahasi KJ, Neurodegeneration in Lurcher mice caused by mutation of δ2 glutamate receptor gene: Nature, 1997; 388; 769-73, pmid: 9285588

20. Araki K, Meguro H, Kushiya E, Selective expression of the glutamate receptor channel delta 2 subunit in cerebellar Purkinje cells: Biochem Biophys Res Commun, 1993; 197; 1267-76, pmid: 7506541

21. Caddy KWT, Biscoe TJ, Structural and quantitative studies on the normal C3H and Lurcher mutant mouse: Philos Trans R Soc London Ser B Biol Sci, 1979; 287; 167-201, pmid: 41272

22. Zanjani SH, Selimi F, Vogel MW, Survival of interneurons and parallel fiber synapses in a cerebellar cortex deprived of Purkinje cells: studies in the double mutant mouse Grid2Lc/−;Bax−/−: J Comp Neurol, 2006; 497; 622-35, pmid: 16739195

23. Wetts R, Herrup K, Interaction of granule, Purkinje and inferior olivary neurons in lurcher chimeric mice. I. Qualitative studies: J Embryol Exp Morphol, 1982a; 68; 87-98, pmid: 7108427

24. Wetts R, Herrup K, Interaction of granule, Purkinje and inferior olivary neurons in lurcher chimeric mice. II. Granule cell death: Brain Res, 1982b; 250; 358-62, pmid: 7171994

25. Cheng SS, Heintz N, Massive loss of mid- and hindbrain neurons during embryonic development of homozygous Lurcher mice: J Neurosci, 1997; 17; 2400-7, pmid: 9065501

26. Resibois A, Cuvelier L, Goffinet AM, Abnormalities in the cerebellum and brainstem in homozygous Lurcher mice: Neuroscience, 1997; 80; 75-90

27. Fortier P, Smith AM, Rossignol S, Locomotor deficits in the cerebellar mutant mouse, Lurcher: Exp Brain Res, 1987; 66; 271-86, pmid: 3595774

28. Lalonde R, Botez MI, Joyal CC, Caumartin M, Motor abnormalities in Lurcher mutant mice: Physiol Behav, 1992; 51; 523-25, pmid: 1523229

29. Krizkova A, Vozeh F, Development of early motor learning and topical motor skills in a model of cerebellar degeneration: Behav Brain Res, 2004; 150; 65-72, pmid: 15033280

30. Lalonde R, Lamarre Y, Smith AM, Does the mutant mouse lurcher have deficits in spatially oriented behaviours?: Brain Res, 1988; 455; 24-30, pmid: 3416189

31. Lalonde R, Thifault S, Absence of an association between motor coordination and spatial orientation in lurcher mutant mice: Behav Genet, 1994; 24; 497-501, pmid: 7872930

32. Porras-Garcia E, Cendelin J, Dominguez-del-Toro E, Purkinje cell loss affects differentially the execution, acquisition and prepulse inhibition of skeletal and facial motor responses in Lurcher mice: Eur J Neurosci, 2005; 21; 979-88, pmid: 15787704

33. Cendelin J, Korelusova I, Vozeh F, The effect of repeated rotarod training on motor skills and spatial learning ability in Lurcher mutant mice: Behav Brain Res, 2008; 189; 65-74, pmid: 18243354

34. Porras-Garcia E, Sanchez-Campusano R, Martinez-Vargas D, Behavioral Characteristics, Associative Learning Capabilities, and Dynamic Association Mapping in an Animal Model of Cerebellar Degeneration: J Neurophysiol, 2010; 104; 346-65, pmid: 20410355

35. Vogel MW, Caston J, Yuzaki M, Mariani J, The Lurcher mouse: Fresh insights from an old mutant: Brain Res, 2007; 1140; 4-18, pmid: 16412991

36. Lalonde R, Strazielle C, Spontaneous and induced mouse mutations with cerebellar dysfunctions: Behavior and neurochemistry: Brain Res, 2007; 1140; 51-74, pmid: 16499884

37. Cendelin J, Vozeh F, Lurcher mouse: Handbook of the Cerebellum and Cerebellar Disorders, 2012, Springer Science+Business Media, doi: 10.1007/978-94-007-1333-8_91 in press

38. Houdek Z, Cendelin J, Kulda V, The comparison of P19-derived neuroprogenitors and naive cells survival after the intracerebellar application in B6CBA mice: Folia Biol Prague, 2011; 57; 162-59, pmid: 21978758

39. McBurney MW, Rogers BJ, Isolation of male embryonal carcinoma cells and their chromosome replication patterns: Dev Biol, 1982; 89; 503-8, pmid: 7056443

40. Pachernik J, Bryja V, Esner M, Neural differentiation of pluripotent mouse embryonal carcinoma cells by retinoic acid: inhibitory effect of serum: Physiol Res, 2005; 54; 115-22, pmid: 15717849

41. Babuska V, Kulda V, Houdek Z, Characterization of P19 cells during retinoic acid induced differentiation: Prague Med Rep, 2010; 111; 288-98

42. Tomey DA, Heckroth JA, Transplantation of normal embryonic cerebellar cell suspensions into the cerebellum of Lurcher mutant mice: Exp Neurol, 1993; 122; 165-70, pmid: 8339786

43. Cendelin J, Korelusova I, Vozeh F, A preliminary study of solid embryonic cerebellar graft survival in adult B6CBA Lurcher mutant and wild type mice: Anat Rec, 2009a; 292; 1986-92

44. Carletti B, Rossi F, Selective rather than inductive mechanisms favour specific replacement of Purkinje cells by embryonic cerebellar cells transplanted to the cerebellum of adult Purkinje cell degeneration (pcd) mutant mice: Eur J Neurosci, 2005; 22; 1001-12, pmid: 16176342

45. Cendelin J, Korelusova I, Vozeh F, The effect of cerebellar transplantation and enforced physical activity on motor skills and spatial learning in adult Lurcher mutant mice: Cerebellum, 2009b; 8; 35-45, pmid: 18850257

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750